Incyte (INCY) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
April 30, 2015 7:00 AM EDT$115 million of 2015 first-quarter net product revenues from Jakafi® (ruxolitinib), representing 66 percent growth over the same period last year $25 million milestone received from Novartis related to the approval of Jakavi® (ruxolitinib) for polycythemia vera in Europe; $16 million product royalties from sales of Jakavi, representing 60 percent growth over the same period last year Primary endpoint met in second Phase III trial of baricitinib in rheumatoid arthritis; additional data disclosures expected during 2015 Recruitment continuing across clinical development portfolio in multiple pivotal and proof-of-concept... More
